journal article·2019-12-04Open access

Clinicopathological and prognostic significance of epithelial cell transforming sequence 2 expression in cancers: a systematic review and meta-analysis

Bin Li, Jun-Ping Lin, Zheng Li, Ci Yin, Jian-Bao Yang, Yu-Qi Meng

Abstract

Numerous studies have investigated the prognostic significance of ECT2 (epithelial cell transforming sequence 2) expression in patients with cancer. Nevertheless, conflicting results have been obtained. We thus performed a meta-analysis to systematically assess the prognostic significance of ECT2 in cancer. Electronic databases (PubMed and EMBASE) were searched for eligible studies. Hazard ratios (HR) and odds ratios (OR) with 95% confidence intervals (CIs) were used to estimate effect sizes. A total of 5,305 patients from 19 articles and 21 studies were included. The pooled results revealed that high ECT2 expression was correlated with advanced TNM stage (OR = 2.17; 95% CI: 1.42-3.32), positive lymph node metastasis (OR = 2.98; 95% CI: 2.28-3.89), distant metastasis (OR = 2.25; 95% CI: 1.03-4.92), and poor tumour differentiation (OR = 2.25; 95% CI: 1.03-4.92). More importantly, high ECT2 expression was significantly associated with poor overall survival (HR = 2.26; 95% CI, 1.84-2.78) and recurrence-free survival (HR = 1.52; 95% CI, 1.24-1.86). Our results suggested that ECT2 is a promising prognostic indicator and therapeutic target for cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Renal and related cancers · Cancer-related gene regulation · Lung Cancer Treatments and Mutations

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou University Second Clinical Medical College

Funding

Cuiying Graduate Supervisor Applicant Training Program of Lanzhou University Second Hospital

References (57)

Show source-provided references
1. 10.3322/caac.2144210.3322/caac.21442 ↗
2. 10.1042/BSR2018068610.1042/BSR20180686 ↗
3. 10.1042/BSR2018109510.1042/BSR20181095 ↗
4. 10.1042/BSR2018105810.1042/BSR20181058 ↗
5. 10.1042/BSR2018237010.1042/BSR20182370 ↗
6. 10.1042/BSR2018061810.1042/BSR20180618 ↗
7. 10.1038/362462a010.1038/362462a0 ↗
8. 10.1038/sj.onc.120912410.1038/sj.onc.1209124 ↗
9. 10.1083/jcb.147.5.92110.1083/jcb.147.5.921 ↗
10. 10.1016/j.ccell.2017.01.00810.1016/j.ccell.2017.01.008 ↗
11. 10.1016/j.biopha.2015.06.00710.1016/j.biopha.2015.06.007 ↗
12. 10.1002/jcp.2557210.1002/jcp.25572 ↗
13. 10.1002/jcp.2868910.1002/jcp.28689 ↗
14. 10.1042/BST2017053110.1042/BST20170531 ↗
15. 10.2147/CMAR.S17003310.2147/CMAR.S170033 ↗
16. 10.1038/s41416-019-0448-z10.1038/s41416-019-0448-z ↗
17. 10.1002/jcb.2745910.1002/jcb.27459 ↗
18. 10.1093/neuonc/noy20710.1093/neuonc/noy207 ↗
19. 10.12659/MSM.90595110.12659/MSM.905951 ↗
20. 10.4103/0028-3886.14127810.4103/0028-3886.141278 ↗
21. 10.1371/journal.pone.001408210.1371/journal.pone.0014082 ↗
22. Jin Y, Yu Y, Shao Q, et al. Up-regulation of ECT2 is associated with poor prognosis in gastric cancer patients. Int J Clin Exp Pathol. 2014;7(12):8724–8731.
23. 10.1016/j.tranon.2018.03.00310.1016/j.tranon.2018.03.003 ↗
24. 10.1136/jclinpath-2017-20456910.1136/jclinpath-2017-204569 ↗
25. 10.1371/journal.pone.018735610.1371/journal.pone.0187356 ↗
26. 10.1002/jcp.2834310.1002/jcp.28343 ↗
27. 10.1002/jcp.2730210.1002/jcp.27302 ↗
28. 10.1002/jcp.2813810.1002/jcp.28138 ↗
29. 10.1136/bmj.327.7414.55710.1136/bmj.327.7414.557 ↗
30. 10.2307/253344610.2307/2533446 ↗
31. 10.1002/jcp.2867710.1002/jcp.28677 ↗
32. 10.1158/1078-0432.CCR-08-167210.1158/1078-0432.CCR-08-1672 ↗
33. 10.1038/s41374-018-0142-410.1038/s41374-018-0142-4 ↗
34. 10.1111/cas.1236310.1111/cas.12363 ↗
35. Sano M, Genkai N, Yajima N, et al. Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients. Oncol Rep. 2006;16:1093–1098.
36. 10.1038/s41598-017-08615-510.1038/s41598-017-08615-5 ↗
37. 10.1016/j.jhep.2015.01.01410.1016/j.jhep.2015.01.014 ↗
38. 10.1007/s12032-016-0872-310.1007/s12032-016-0872-3 ↗
39. 10.1007/s12094-015-1428-210.1007/s12094-015-1428-2 ↗
40. Xiu Y, Liu W, Wang T, et al. Overexpression of ECT2 is a strong poor prognostic factor in ER+ breast cancer. Mol Clin Onc. 2019;10:497–505.
41. Li Y, Cai X, Chen B, et al. Overexpression of epithelial cell transforming 2 protein in colorectal carcinoma predicts a poor prognosis. Exp Ther Med. 2017;14:4862–4868.
42. 10.2353/ajpath.2008.08004310.2353/ajpath.2008.080043 ↗
43. Zhi T, Jiang K, Xu X, et al. MicroRNA-520d-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting PTTG1. Am J Transl Res. 2017;9(11):4872–4887.
44. 10.3892/etm.2016.358410.3892/etm.2016.3584 ↗
45. 10.1002/jcp.2689410.1002/jcp.26894 ↗
46. 10.1002/jcp.2219710.1002/jcp.22197 ↗
47. 10.7150/jca.2482410.7150/jca.24824 ↗
48. 10.1158/1541-7786.MCR-11-061610.1158/1541-7786.MCR-11-0616 ↗
49. 10.1016/j.ajpath.2012.04.01110.1016/j.ajpath.2012.04.011 ↗
50. 10.1177/194760191351485110.1177/1947601913514851 ↗
51. 10.1002/jcp.2246310.1002/jcp.22463 ↗
52. 10.1158/1541-7786.MCR-13-0371-T10.1158/1541-7786.MCR-13-0371-T ↗
53. 10.1016/j.ccell.2016.12.01010.1016/j.ccell.2016.12.010 ↗
54. 10.1002/jcb.2687610.1002/jcb.26876 ↗
55. 10.1016/j.biopha.2013.03.01310.1016/j.biopha.2013.03.013 ↗
56. 10.12659/MSM.90538810.12659/MSM.905388 ↗
57. 10.1158/0008-5472.CAN-15-155310.1158/0008-5472.CAN-15-1553 ↗